← Evidence map

ArticleJournal of Cancer2026

Long-Term Empagliflozin Treatment (50 Days) Attenuates Protease Activity, Migration, and Stemness-Associated Phenotypes in BFTC-909 Renal Pelvis Transitional Cell Carcinoma Cells.

Yi-Hsun Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Long-Term Empagliflozin Treatment (50 Days) Attenuates Protease Activity, Migration, and Stemness-Associated Phenotypes in BFTC-909 Renal Pelvis Transitional Cell Carcinoma Cells. | Socratic